The Current Ratio as of September 2024 (TTM) for VYNE Therapeutics Inc. (VYNE) is 7.13

According to VYNE Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.13. This represents a change of -19.90% compared to the average of 8.90 of the last 4 quarters.

VYNE Therapeutics Inc. (VYNE) Historical Current Ratio (quarterly & annually)

How has VYNE Current Ratio performed in the past?

The mean historical Current Ratio of VYNE Therapeutics Inc. over the last ten years is 13.28. The current 7.13 Current Ratio has changed 5.27% with respect to the historical average. Over the past ten years (40 quarters), VYNE's Current Ratio was at its highest in in the September 2018 quarter at 19.16. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

VYNE Therapeutics Inc. (VYNE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of VYNE Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

VYNE Therapeutics Inc. (VYNE) Average Current Ratio

How has VYNE Current Ratio performed in the past?

The current Current Ratio of VYNE Therapeutics Inc. (VYNE) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

VYNE Therapeutics Inc. (VYNE) Current Ratio vs. Peers

How is VYNE’s Current Ratio compared to its peers?

VYNE Therapeutics Inc.’s Current Ratio is greater than Akari Therapeutics, Plc (0.58), greater than Salarius Pharmaceuticals, Inc. (2.98), greater than Axcella Health Inc. (0.80), less than Magenta Therapeutics, Inc. (14.64), greater than Histogen Inc. (4.05), greater than First Wave BioPharma, Inc. (1.21), greater than SAB Biotherapeutics, Inc. (5.24), greater than Vaccinex, Inc. (0.42), greater than GeoVax Labs, Inc. (0.60), greater than Catalyst Biosciences, Inc. (0), greater than Unicycive Therapeutics, Inc. (3.37), greater than Pulmatrix, Inc. (6.33), greater than Cidara Therapeutics, Inc. (4.25), greater than Phio Pharmaceuticals Corp. (3.47), less than Kronos Bio, Inc. (8.49), greater than Veracyte, Inc. (4.44), greater than Atreca, Inc. (1.58), greater than Longeveron Inc. (4.18), greater than Lyra Therapeutics, Inc. (3.60), greater than Revelation Biosciences, Inc. (1.10), less than Zura Bio Limited (12.57), greater than ZyVersa Therapeutics, Inc. (0.06), greater than TransCode Therapeutics, Inc. (1.25),

Build a custom stock screener for VYNE Therapeutics Inc. (VYNE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like VYNE Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

VYNE Therapeutics Inc. (VYNE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like VYNE Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.